search
Back to results

Adjuvant Nutrition for Critically Ill Trauma Patients

Primary Purpose

Trauma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Juven (nutritional), HMB (nutritional)
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Trauma

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Critically injured trauma patients with an Injury Severity Score (ISS) >18 Candidate for enteral feeding Life expectancy >48 hours Total Bilirubin less than or equal to 2.5 mg/dl Serum Creatinine less than 3.0 mg/dl. Must be able to start supplements within 72 h Patient must reside in geographical area of Las Vegas, Nevada Exclusion Criteria Pregnant Genetic or immune disorder Known hepatitis 3rd degree burns involving more than 15% of the body Use of other investigational drugs Steroid use Malignancy HIV Congestive heart failure Inflammatory bowel disease Implanted pacemaker or defibrillator

Sites / Locations

  • University Medical Trauma Center/UNSOM

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
August 11, 2003
Last Updated
January 12, 2010
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT00067132
Brief Title
Adjuvant Nutrition for Critically Ill Trauma Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2010
Overall Recruitment Status
Completed
Study Start Date
March 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

5. Study Description

Brief Summary
Of the four million trauma cases each year that will require hospitalization, 200,000 will be classified as severe trauma. During the hospital stay, malnutrition is a major complication in about 50% of the patient population. The result is muscle wasting which is a major risk factor for increased morbidity and mortality. In this study we postulate that supplementation with beta-hydroxy-beta-methylbutyrate (HMB), arginine and glutamine (HMB/Arg/Gln)or HMB alone to these severely traumatized patients can stem the loss of muscle tissue and whole body nitrogen and in turn decrease morbidity and mortality. This hypothesis is based on two recent studies showing the same nutritional mixture of HMB/Arg/Gln can reverse the muscle wasting associated with AIDS and Cancer. The hypermetabolic state seen in AIDS and cancer have a similar multifactorial etiology as seen in trauma. There is an increase in the mobilization of fat and muscle, increased or normal metabolic rate, increased protein breakdown, and an increased or normal glucose turnover. In addition, HMB alone has been shown to reduce nitrogen loss, decrease muscle proteolysis and muscle damage within the first 48 hours to three weeks after initiating supplementation during a strenuous exercise program. Male and female patients (n=100) will be recruited at the time of admittance to the Trauma ICU with an ISS of greater than 18. Patients who meet the inclusion/exclusion criteria will be randomized to receive either 1) standard tube feed plus HMB/Arg/Gln, 2) standard tube feed plus HMB alone, or 3)standard tube feed (control) in a double-blinded fashion. Clinical outcomes measures will be assessed through out the hospital stay and on an outpatient basis at weeks 4 and 12. Muscle proteolysis and nitrogen economy will be evaluated on daily basis while in the hospital and after 4 weeks on an out patient basis. If as expected, Phase I results confirm the effectiveness of the nutrient mixture in trauma patients, expanded multicenter studies will be proposed in Phase II.
Detailed Description
OBJECTIVES: To compare the effectiveness of immediate nutritional intervention with either HMB, arginine, and glutamine or HMB alone with that of a placebo supplement in critically ill trauma patients on: decreasing muscle protein turnover and nitrogen loss improving nutritional status, improving clinical outcomes, preventing total body weight and skeletal muscle loss and improving immune status OUTLINE: This is a double blind, placebo-controlled randomized clinical study. After receiving informed consent for participation in the study from the next of kin, patients will be randomly assigned to one of the 3 treatment arms: Arm 1: Standard tube feed plus a nutritional supplement supplying 3 grams of HMB, 14 grams of arginine and 14 grams of glutamine per day. The supplement will be divided into two equal dosages with one dose being given in the morning and one dose given in the evening. Arm 2: Standard tube feed plus a nutritional supplement supplying 3 grams of HMB. This nutritional supplement will contain gelatin and non-essential amino acids to be isonitrogenous with the supplement in Arm 1. The supplement will also be divided into two equal dosages with one dose being given in the morning and one dose given in the evening. Arm 3: Standard tube feed plus a nutritional supplement supplying a mixture of gelatin and amino acids to be isonitrogenous with the supplement in Arm 1. The supplement will again be divided into two equal dosages with one dose being given in the morning and one dose given in the evening. Patients will receive the nutritional supplements for a period of 4 weeks. If a patient leaves the hospital or ICU before that time and/or discontinues the enteral nutrition support, the supplements will be continued orally for the full 4-week period. Several clinical outcome measures will be followed such as hospital length of stay, ICU length of stay, mortality, number of ventilator days, and incidence of infectious complications. Clinical outcomes will be assessed during the hospital stay and at 4 and 12 weeks. Muscle protein metabolism will be measured during the hospital stay and at 4 weeks. Nutritional status while hospitalized will be assessed by serum pre-albumin levels on days 0,1, 3, 7, and 14. White blood count, number of confirmed infections and C-Reactive Protein levels will serve as proxies for immune status.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trauma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Juven (nutritional), HMB (nutritional)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Critically injured trauma patients with an Injury Severity Score (ISS) >18 Candidate for enteral feeding Life expectancy >48 hours Total Bilirubin less than or equal to 2.5 mg/dl Serum Creatinine less than 3.0 mg/dl. Must be able to start supplements within 72 h Patient must reside in geographical area of Las Vegas, Nevada Exclusion Criteria Pregnant Genetic or immune disorder Known hepatitis 3rd degree burns involving more than 15% of the body Use of other investigational drugs Steroid use Malignancy HIV Congestive heart failure Inflammatory bowel disease Implanted pacemaker or defibrillator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John A Rathmacher, Ph.D.
Organizational Affiliation
Metabolic Technologies Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Trauma Center/UNSOM
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89102
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11975938
Citation
May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002 Apr;183(4):471-9. doi: 10.1016/s0002-9610(02)00823-1.
Results Reference
background
PubMed Identifier
10850936
Citation
Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA, Rathmacher JA. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000 May-Jun;24(3):133-9. doi: 10.1177/0148607100024003133.
Results Reference
background
PubMed Identifier
10978853
Citation
Panton LB, Rathmacher JA, Baier S, Nissen S. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Nutrition. 2000 Sep;16(9):734-9. doi: 10.1016/s0899-9007(00)00376-2.
Results Reference
background
PubMed Identifier
8941534
Citation
Nissen S, Sharp R, Ray M, Rathmacher JA, Rice D, Fuller JC Jr, Connelly AS, Abumrad N. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol (1985). 1996 Nov;81(5):2095-104. doi: 10.1152/jappl.1996.81.5.2095.
Results Reference
background
PubMed Identifier
12192323
Citation
Williams JZ, Abumrad N, Barbul A. Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg. 2002 Sep;236(3):369-74; discussion 374-5. doi: 10.1097/00000658-200209000-00013.
Results Reference
background

Learn more about this trial

Adjuvant Nutrition for Critically Ill Trauma Patients

We'll reach out to this number within 24 hrs